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Introduction
Heparin cofactor II (HCII) is a serine protease inhibitor
(serpin) that inactivates thrombin rapidly in the presence
of certain glycosaminoglycans (reviewed in ref. 1). HCII
does not inhibit other proteases involved in coagulation
or fibrinolysis. Thrombin stimulates platelet aggregation,
promotes coagulation by cleavage of fibrinogen and acti-
vation of factors V, VIII, XI, and XIII, and inhibits fibri-
nolysis by activation of a plasma carboxypeptidase (2).
Conversely, when thrombin binds to thrombomodulin
on the surface of endothelial cells, it activates protein C,
which inhibits further thrombin generation. Thrombin
also engages in a variety of activities unrelated to hemo-
stasis (3). For example, it causes proliferation of fibrob-
lasts and other cells, induces monocyte chemotaxis, pro-
motes adhesion of neutrophils to endothelial cells, and
inhibits neurite outgrowth. HCII could potentially regu-
late the activity of thrombin in one or more of these
diverse biological processes.
The rate of inhibition of thrombin by HCII increases
more than 1000-fold in the presence of heparin, heparan
sulfate, or dermatan sulfate (4). HCII is unique among
serpins in its ability to be stimulated by dermatan sulfate
and binds to a minor subpopulation of dermatan sulfate
oligosaccharides (5). By contrast, antithrombin binds to
a specific pentasaccharide structure in heparin or
heparan sulfate and is thereby stimulated to inhibit
thrombin and other coagulation proteases (especially
factors Xa and IXa) (1). The distribution of specific gly-
cosaminoglycans on the cell surface or in the ECM may
serve to localize protease inhibition by HCII and
antithrombin to different sites. Cultured fibroblasts and
vascular smooth muscle cells synthesize proteoglycans
that stimulate inhibition of thrombin by HCII, but
endothelial cells do not, suggesting that HCII may inhib-
it thrombin at sites outside the vascular lumen (6, 7).
Although the physiologic function of HCII is
unknown, the presence of thrombin-HCII complexes in
human plasma indicates that HCII inhibits thrombin
in vivo (8, 9). HCII is synthesized by the liver and circu-
lates in human plasma at a concentration of about 1
µM (10). Turnover studies of labeled HCII in humans
suggest that about 40% of the protein equilibrates with
an extravascular compartment (11), but the tissue dis-
tribution of HCII has not been thoroughly investigated.
HCII has been detected in the intima of normal human
arteries, and the ability of dermatan sulfate in the arte-
rial wall to stimulate HCII is decreased in atheroscle-
rotic lesions (12, 13). During pregnancy, both the mater-
nal and the fetal blood contain trace amounts of a
dermatan sulfate proteoglycan that stimulates throm-
bin inhibition by HCII (14). The placenta is rich in der-
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matan sulfate and may be the source of the circulating
proteoglycan, suggesting that HCII could be activated
locally to inhibit coagulation in the placenta (15).
Chemotactic peptides are released when HCII is par-
tially degraded by neutrophil proteases, suggesting a
possible direct role for HCII in inflammation (16). HCII
could also participate in wound healing by regulating
the mitogenic or chemotactic activities of thrombin.
Several patients with inherited HCII deficiency (∼50%
of normal) and histories of venous thromboembolic dis-
ease have been reported (17, 18). In one study, however,
4 of 379 apparently healthy individuals had HCII levels
less than 60% of normal (19). Thus, heterozygous defi-
ciency of HCII may be a coincidental finding in about
1% of patients with venous thrombosis and does not
appear to be a strong risk factor for development of this
disease (20). Two sisters who appeared to be homozy-
gous for HCII deficiency (HCII activity 10–15% of nor-
mal) have been reported (21); one of these individuals
was also heterozygous for antithrombin deficiency and
had recurrent venous thromboembolism. Human sub-
jects who completely lack HCII have not been identified.
With the aim of elucidating the physiologic function(s)
of HCII, we have generated a mouse model of HCII defi-
ciency by targeted gene disruption in embryonic stem
cells. HCII-deficient mice are viable and fertile, and they
do not appear to have spontaneous thrombosis or other
morphologic abnormalities. In comparison with wild-
type animals, however, they demonstrate a significantly
shorter time to thrombotic occlusion of the carotid artery
after photochemically induced endothelial cell injury.
These observations suggest that a function of HCII
might be to inhibit thrombosis in the arterial circulation.
Methods
Construction of the targeting vector. PCR primers 
(5′-CTTCTTTCTCTCATCACATTTATG and 5′-CTTG-
GAAAAGCTGCAGGATGTTG) that amplify a 271-bp frag-
ment in exon 1 of the mouse HCII gene (22) were used
to screen a bacterial artificial chromosome (BAC)
library made from 129/SvJ mouse genomic DNA
(Genome Systems Inc., St. Louis, Missouri, USA). Two
clones were isolated, each containing more than 100 kb
of genomic DNA. A 6-kb EcoRV fragment that includ-
ed about 3 kb of 5′ flanking sequence, exon 1, and
about 2 kb of intron 1 was isolated from one of the
BAC clones and subcloned into the EcoRV site of pBlue-
script II SK(+) (Stratagene, La Jolla, California, USA).
The vector was then cleaved with EcoRI to remove the
exon 1 and intron 1 sequences and ligated to a 1.6-kb
EcoRI fragment of pPGKneo-I (Embryonic Stem Cell
Core, Washington University), which contained the
phosphoglycerate kinase promoter and the neomycin
phosphotransferase gene (neo) flanked by loxP
sequences. Ligation of the neo cassette occurred in the
same transcription orientation as the HCII gene. A 4-kb
BamHI fragment extending from the middle of intron
1 through intron 3 of the HCII gene was isolated from
the other BAC clone and inserted into the BamHI mul-
tiple cloning site of pBluescript to yield the targeting
vector shown in Figure 1a. The final construct con-
tained a 5′ arm of 2.9 kb and a 3′ arm of 3.6 kb of HCII
genomic sequence flanking the neo cassette.
Generation of HCII-deficient mice. The targeting vector
was linearized with NotI and introduced into 129/SvJ-
derived RW-4 embryonic stem cells (Embryonic Stem
Cell Core, Washington University) by electroporation.
G418-resistant clones were screened for homologous
recombination at the HCII locus by Southern
hybridization of SacI digests, using a 329-bp probe (3′-
probe) to a DNA sequence in exon 4 and an approxi-
mately 500-bp probe (5′-probe) to a DNA sequence in
the 5′ flanking region of the HCII gene; both probes
hybridized to sequences external to the targeting vec-
tor (Figure 1a). Cells from a correctly targeted clone
were injected into C57BL/6 blastocysts, which were
then implanted into pseudopregnant females. The
resulting chimeric males were crossed with wild-type
C57BL/6 females to produce F1 agouti offspring that
were genotyped by Southern hybridization of DNA
from tail biopsies. F1 heterozygotes were crossed to pro-
duce homozygous HCII-deficient mice. These mice
were backcrossed for six generations with wild-type
C57BL/6 animals to produce a nearly congenic strain
of mice containing the HCII-null allele. N6 heterozy-
gotes were crossed to produce HCII+/+ and HCII–/– mice.
mRNA analysis. Total RNA was purified from adult
mouse livers by acid phenol–guanidinium thio-
cyanate–chloroform extraction (23). Northern blots of
the RNA were hybridized with an 891-bp cDNA probe
encoding the 3′ half of exon 2 and all of exons 3 and 4.
The blots were hybridized separately with a 625-bp
probe to the neo cassette.
Western blots. Plasma (0.1 or 0.3 µl) was subjected to
electrophoresis on a 7.5% SDS polyacrylamide gel under
reducing conditions. The proteins were transferred to a
nitrocellulose membrane, which was then blocked with
5% milk and incubated with affinity-purified goat anti-
human HCII IgG (Affinity Biologicals Inc., Hamilton,
Ontario, Canada) at a concentration of 3 µg/ml for 1
hour at room temperature. The membrane was subse-
quently washed and incubated with horseradish perox-
idase–conjugated mouse anti-goat IgG (A9452; Sigma
Chemical Co., St. Louis, Missouri, USA) at a 1:5000 dilu-
tion. Immobilized antibody was detected with Super-
Signal West Pico Chemiluminescent Substrate (Pierce
Chemical Co., Rockford, Illinois, USA) according to the
manufacturer’s instructions.
Inhibitor activity assays. HCII activity was determined
by measuring the amount of thrombin inhibited in
mouse plasma supplemented with dermatan sulfate.
Plasma (2 µl) was mixed with 50 µg/ml porcine skin
dermatan sulfate (Sigma Chemical Co.) and 16 nM
human α-thrombin (Haematologic Technologies Inc.,
Essex Junction, Vermont, USA) in a total volume of 100
µl of buffer containing 50 mM Tris-HCl, 150 mM
NaCl, and 1 mg/ml poly(ethylene glycol) 8000, pH 7.4
(TS/PEG buffer). Thrombin was added last to initiate
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the reaction. After a 60-second incubation at room
temperature, 500 µl of 100 µM tosyl-Gly-Pro-Arg-p-
nitroanilide (Chromozym TH; Roche Molecular Bio-
chemicals, Indianapolis, Indiana, USA) in TS/PEG was
added, and the absorbance at 405 nm was determined
continuously for 100 seconds. The rate of change of
absorbance was proportional to the concentration of
active thrombin that remained in the incubation. The
molar concentration of HCII in plasma was calculated
from the amount of thrombin inhibited, assuming 1:1
stoichiometry of inhibition.
Antithrombin activity was determined by measuring
the amount of factor Xa inhibited in plasma supple-
mented with heparin. Plasma (0.3 µl) was mixed with 1
U/ml porcine intestinal heparin (Elkins-Sinn Inc.,
Cherry Hill, New Jersey, USA) and 11 nM human factor
Xa (Haematologic Technologies) in 100 µl of TS/PEG
buffer. Factor Xa was added last to initiate the reaction.
After a 60-second incubation at room temperature, 500
µl of 500 µM MeO-CO-D-cyclohexylglycyl-Gly-Arg-p-
nitroanilide (Spectrozyme fXa; American Diagnostica
Inc., Greenwich, Connecticut, USA) in TS/PEG was
added, and the absorbance at 405 nm was determined
continuously for 100 seconds. The rate of change of
absorbance was proportional to the concentration of
active factor Xa that remained in the incubation. The
molar concentration of antithrombin was calculated
from the amount of factor Xa inhibited, assuming 1:1
stoichiometry of inhibition.
Blood tests. Routine blood tests of four HCII–/– males,
four HCII–/– females, four HCII+/+ males, and three
HCII+/+ females, all approximately 6 months of age,
were performed using standard methods in the Divi-
sion of Comparative Medicine, Washington University.
The tests included complete blood counts with white
blood cell differentials and assays for urea nitrogen,
creatinine, total protein, alanine aminotransferase, and
aspartate aminotransferase.
Necropsies. Necropsies of four HCII–/– mice approxi-
mately 6 months of age (two males and two females)
were performed by a veterinary pathologist in the Divi-
sion of Comparative Medicine, Washington University.
Histologic examination included the lung, heart, stom-
ach, intestinal tract, brain, liver, kidney, spleen, pan-
creas, aorta, adrenal glands, ovary, uterus, testes, and
accessory sex glands.
Arterial thrombosis model. Carotid artery thrombosis
was induced as described previously (24). Briefly, adult
male and female mice were anesthetized with intraperi-
toneal sodium pentobarbital, secured in the supine
position, and placed under a dissecting microscope. The
right common carotid artery was isolated through a
midline cervical incision, and an ultrasonic flow probe
(model 0.5 VB; Transonic Systems Inc., Ithaca, New
York, USA) was applied. A 1.5-mW, 540-nm laser beam
(Melles Griot Inc., Carlsbad, California, USA) was
applied to the artery from a distance of 6 cm. Rose ben-
gal dye (50 mg/kg body weight; Fisher Scientific Co.,
Fair Lawn, New Jersey, USA) was then injected into the
tail vein, and flow in the vessel was monitored until
complete occlusion occurred. Five minutes before the
injection of rose bengal dye, some animals were inject-
ed with purified human HCII (25) or ovalbumin (Sigma
Chemical Co.) in PBS to achieve a plasma concentration
of about 1 µM. Specifically, 6.7 µl of a 4.7 µM protein
solution was injected per gram body weight; the plasma
volume was assumed to be 31.5 µl/g. Carotid artery seg-
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Figure 1
Targeted disruption of the murine HCII gene. (a) Restriction map of
the HCII locus and design of a replacement vector. The boxes repre-
sent exons 1–4 of the HCII gene. The thick lines represent genomic
DNA; the thin lines, vector DNA. The targeting vector was con-
structed by insertion of the neomycin phosphotransferase gene (neo)
between the EcoRI and BamHI sites of the HCII gene. (b) Southern
blots of genomic DNA isolated from the tails of 4- to 6-week-old
mice and digested with SacI. The restriction fragments were detected
with probes (5′-probe and 3′-probe) that hybridized with sequences
external to the genomic DNA present in the targeting vector. (c)
Northern blot of total liver RNA obtained from adult mice. The blot
was first hybridized with a cDNA probe containing sequences pres-
ent in exons 2–4 of the HCII gene. It was then stripped and rehy-
bridized with a probe containing sequences present in the neo cas-
sette. (d) Western blot of mouse plasma probed with goat
anti-human HCII IgG. The 68-kDa and 72-kDa bands represent two
glycoforms of HCII that are present in normal mouse plasma (22).
HCII genotypes (+/+, +/–, and –/–) are indicated in panels b–d.
ments were fixed in 10% formalin, cross-sectioned, and
stained with hematoxylin and eosin for examination by
light microscopy.
Statistical analysis. Statistical significance was deter-
mined with the Student two-tailed t test (http://facul-
ty.vassar.edu/lowry/VassarStats.html). A P value less
than 0.05 was considered significant.
Results
A cDNA clone for murine HCII was isolated previously,
and Southern hybridization of genomic DNA indicated
the presence of a single HCII gene (22). In the current
study, genomic clones were isolated from a BAC library
constructed with DNA from 129/SvJ mice. A partial
restriction map of the HCII locus is shown in Figure 1a.
A targeting vector was constructed by insertion of the
neomycin phosphotransferase gene (neo) between the
EcoRI and BamHI sites of the HCII gene, which resulted
in deletion of about 1 kb of 5′ flanking sequence, exon 1,
and part of intron 1. Since exon 1 encodes approximate-
ly the N-terminal half of HCII, any gene product synthe-
sized from the targeted locus would be expected to be
inactive. RW-4 embryonic stem cells derived from 129/SvJ
mice were transfected with the linearized targeting vector
and selected for growth in the presence of G418. Homol-
ogous recombination at the HCII locus was detected by
Southern blotting with a probe that hybridized to a DNA
sequence in exon 4, external to the genomic sequence
included in the targeting vector. Digestion of DNA with
SacI yielded a 15-kb fragment from the wild-type allele
and a 5-kb fragment from the targeted allele.
Homologous recombination occurred in 5 of 684
G418-resistant embryonic stem cell clones. Embryonic
stem cells from one clone with the targeted allele were
injected into C57BL/6 blastocysts and implanted into
pseudopregnant females. The resulting chimeric males
were crossed with wild-type C57BL/6 females to pro-
duce F1 offspring that were genotyped by Southern blot-
ting of DNA from tail biopsies. Correct targeting of the
HCII locus was verified with probes that hybridized to
sequences both 5′ and 3′ to the DNA included in the tar-
geting vector (Figure 1b). Crosses of heterozygous F1
animals yielded 250 offspring, with HCII–/– pups being
present at close to the expected mendelian frequency
(24.8% HCII+/+, 53.6% HCII+/–, and 21.6% HCII–/–). Sub-
sequent crosses in which both parents were HCII–/– pro-
duced litters similar in size (6.8 ± 3.0 pups per litter, 
n = 11 litters) to those obtained from crosses of HCII+/–
mice (6.7 ± 3.1 pups per litter, n = 38 litters).
Northern blots of total liver RNA isolated from adult
HCII+/+ mice demonstrated a single HCII mRNA species
of about 2.5 kb, as expected from previous studies (22);
this mRNA was absent in HCII–/– mice (Figure 1c). A 1.2-
kb transcript containing neo sequences was detected in
HCII+/– and HCII–/– mice but not in wild-type animals. A
separate, 1.4-kb transcript containing sequences present
in exons 2–4 of the HCII gene was also present in HCII+/–
and HCII–/– mice. Since plasma from HCII-null mice did
not contain detectable HCII antigen or activity (see
below), the 1.4-kb transcript was not investigated further.
Western blots of plasma probed with a polyclonal anti-
body indicated the presence of two previously described
glycoforms of HCII (68 kDa and 72 kDa) in wild-type
mice (22). Both glycoforms were absent in HCII–/– mice,
and intermediate levels were present in HCII+/– mice (Fig-
ure 1d). No bands of lower molecular weight were
observed in plasma of mice with the targeted HCII allele,
strongly suggesting that the abnormal 1.4-kb HCII tran-
script did not give rise to HCII-like polypeptides in the
circulation. Biochemical assays confirmed the absence of
HCII activity (i.e., dermatan sulfate–dependent thrombin
inhibition) in plasma obtained from HCII–/– mice 
(0.00 ± 0.03 µM, mean ± SD) in contrast to HCII+/–
(0.16 ± 0.02 µM) and HCII+/+ (0.36 ± 0.05 µM) mice 
(Figure 2a). Antithrombin activity (i.e., heparin-depend-
ent factor Xa inhibition) was similar in all three geno-
types (Figure 2b).
At one year of age, homozygous HCII-deficient mice
were indistinguishable from their wild-type and het-
erozygous littermates in weight, appearance, and survival.
Necropsies of four adult HCII–/– animals revealed no
gross or microscopic abnormalities. Blood tests of HCII–/–
mice (n = 8), including complete blood count with white
blood cell differential, urea nitrogen, creatinine, total pro-
tein, alanine aminotransferase, and aspartate amino-
transferase, were within normal limits and did not differ
significantly from those of wild-type mice (n = 7).
The time to formation of an occlusive thrombus in the
carotid artery following photochemically induced
endothelial injury was shorter in HCII-deficient mice
than in wild-type controls. Previous studies indicated
that the base-line occlusion time in this model varies with
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Figure 2
Biochemical assays of mouse plasma. (a) HCII activ-
ity is expressed as the amount of thrombin inhibit-
ed per liter of plasma in the presence of dermatan
sulfate. (b) Antithrombin (AT) activity is expressed
as the amount of factor Xa inhibited per liter of plas-
ma in the presence of heparin.
the mouse strain (26). For our initial experiments, HCII–/–
mice and their HCII+/+ littermates were studied at 6–8
months of age. These animals were obtained from cross-
es of heterozygous F1 animals to insure that potential
modifier genes present in the C57BL/6 and 129/SvJ back-
grounds would be distributed at equal frequencies in
both sets of animals (Figure 3a). The time to arterial
occlusion was 14.9 ± 3.2 minutes in HCII–/– mice com-
pared with 23.7 ± 5.1 minutes in HCII+/+ mice (mean ±
SD, n = 5 in each group). This difference is statistically sig-
nificant (P = 0.012). To determine whether the difference
in occlusion time is reproducible in mice with a more
homogeneous genetic background, HCII heterozygotes
were backcrossed for six generations with wild-type
C57BL/6 animals to yield animals with about 97%
C57BL/6 gene content. The N6 heterozygotes were
crossed to produce HCII+/+ and HCII–/– mice, which were
studied at 3–4 months of age. In the HCII–/– mice, the
time to arterial occlusion was 27.7 ± 5.0 minutes (n = 10)
compared with 38.6 ± 10.2 minutes in the HCII+/+ mice 
(n = 18) (Figure 3b). Although the occlusion times of both
the wild-type and the HCII-null animals were longer than
those of mice with a mixed genetic background, the
absolute difference was similar (11 minutes vs. 9 minutes)
and was statistically significant (P = 0.004). The abnor-
mally short arterial occlusion time of the HCII–/– mice
was corrected by intravenous injection of purified HCII 5
minutes prior to induction of vascular injury (46.7 ± 10.8
minutes, n = 6) but not by injection of the noninhibitory
serpin ovalbumin (27.4 ± 8.5 minutes, n = 7) (Figure 3b).
Representative recordings of carotid blood flow are
shown in Figure 4a. Cessation of blood flow was
accompanied by the appearance of a pearly white occlu-
sive filling defect in the lumen of the artery that was vis-
ible through the dissecting microscope. Sections of the
occluded arteries stained with hematoxylin and eosin
revealed no gross histologic differences between throm-
bi formed in HCII+/+ and HCII–/– animals (Figure 4, b
and c). It was apparent from transient reductions in
blood flow as well as direct observation through the
dissecting microscope that a dynamic state of throm-
bus formation and lysis occurred throughout the peri-
od of vascular injury prior to complete occlusion.
Discussion
Unlike antithrombin-deficient mice, which die in utero
with extensive fibrin(ogen) deposition in the liver and
myocardium (27), HCII-deficient mice apparently
undergo normal fetal development and are born at the
expected mendelian frequency. Their subsequent growth
and survival is normal up to at least 1 year of age, and
they do not demonstrate any obvious morphologic
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Figure 3
Effect of HCII deficiency on thrombotic occlusion of the carotid artery.
Blood flow in the common carotid artery was monitored continuously
with an ultrasonic flow probe. Local endothelial injury was induced by
application of a 540-nm laser beam to the carotid artery followed by
injection of rose bengal dye (50 mg/kg) into the lateral tail vein. (a) Mice
with a mixed C57BL/6-129/SvJ genetic background. (b) Mice back-
crossed for six generations into the C57BL/6 background. Five minutes
before the injection of rose bengal dye, some of these mice were injected
intravenously with purified human HCII or ovalbumin as indicated to
achieve a plasma level of about 1 µM.
Figure 4
Thrombotic occlusion of the carotid
artery. (a) Representative blood flow
recordings of HCII–/– (red) and HCII+/+
(blue) mice. Rose bengal dye was injected
at time = 0 min. (b and c) Photomicro-
graphs of cross sections of carotid arteries
from HCII+/+ and HCII–/– mice, respective-
ly, harvested after complete cessation of
blood flow. The sections were stained with
hematoxylin and eosin. 
abnormalities on gross or microscopic examination.
Blood tests also indicate normal hematopoiesis as well
as normal liver and kidney function. Thus, we find no
evidence of thrombosis or bleeding secondary to dis-
seminated intravascular coagulation, which are typical
manifestations of deficiencies of several other anticoag-
ulant proteins, including protein C (28), tissue factor
pathway inhibitor (29), and antithrombin (27). Further
experiments may show that HCII deficiency is similar to
protein Z deficiency, in which a spontaneous prothrom-
botic phenotype occurs only when combined with the
homozygous factor VLeiden genotype (30).
Indirect evidence suggests that HCII activity may be
increased in human pregnancy. During the third
trimester, plasma HCII levels are about 150% of normal
(31, 32), both maternal and fetal plasma contain trace
amounts of a dermatan sulfate proteoglycan that stimu-
lates thrombin inhibition by HCII (14), and thrombin-
HCII complexes are elevated approximately fourfold (8).
Conversely, HCII levels are decreased to about 50% of nor-
mal in women with severe pre-eclampsia (32), suggesting
that decreased HCII activity may be associated with pla-
cental dysfunction. Nevertheless, HCII does not appear
to be required for normal gestation in mice, since crosses
in which both parents are HCII-deficient produce litters
similar in size to those from heterozygous matings.
In contrast to the benign phenotype of unchallenged
HCII-deficient mice, our experiments suggest that HCII
plays an important role in maintaining blood flow after
injury to the arterial endothelium. In these experi-
ments, rose bengal dye in the lumen of the carotid
artery was excited by transillumination with a green
light laser to generate singlet oxygen. Previous studies
have shown that this treatment causes membrane dam-
age, resulting in detachment of the endothelial cells
from a localized segment of the vessel wall followed by
formation of a thrombus that is rich in platelets and
fibrin (33). The mean time to thrombotic occlusion of
the carotid artery was significantly shorter in HCII-defi-
cient mice than in their wild-type littermates, both in a
mixed C57BL/6-129/SvJ background and in a nearly
congenic C57BL/6 strain. In a previous study, the
carotid occlusion time was reduced to a similar degree
in apoE-deficient mice fed a high-cholesterol diet (34).
By contrast, the occlusion time was prolonged approx-
imately twofold in mice deficient in plasminogen acti-
vator inhibitor-1 (24, 35). Thus, the rose bengal model
appears to be sensitive to structural alterations in the
vessel wall associated with atherosclerosis as well as to
systemic changes in the fibrinolytic system. The abnor-
mally short occlusion time of HCII-deficient mice was
corrected by intravenous injection of purified HCII (2.1
µg/g) to achieve a plasma concentration of about 1 µM
prior to photochemical injury. As reported previously,
intravenous injection of a much larger dose of purified
HCII (84 µg/g) prior to photochemical injury of the
femoral artery prolonged the occlusion time from 17
minutes to 31 minutes in wild-type rats (36). This
experiment, together with our results, suggests that
HCII exerts an antithrombotic effect after photochem-
ical injury to the arterial endothelium.
An important question raised by these studies is
whether the protective effect of HCII depends on cataly-
sis of the thrombin-HCII reaction by glycosaminoglycans
in the vessel wall. Purified human HCII inhibits throm-
bin with second-order rate constants of about 6 × 104 M–1
min–1 in the absence of a glycosaminoglycan and about 2
× 108 M–1 min–1 in the presence of dermatan sulfate or
heparin (37). If one assumes that mouse HCII inhibits
thrombin with similar kinetics and is present in plasma
at a concentration of 0.35 µM (Figure 2), then the half-
time for inhibition of thrombin by HCII in mouse plas-
ma would be about 30 minutes in the absence of a gly-
cosaminoglycan. However, it is likely that antithrombin
dominates thrombin inhibition in the fluid phase,
because it is present at a higher concentration in plasma
(2 µM, Figure 2) and it inhibits thrombin more rapidly
than HCII does in the absence of a glycosaminoglycan (1).
Binding of HCII to subendothelial glycosaminoglycans
could potentially concentrate the HCII and dramatically
increase the rate of thrombin inhibition at the site of arte-
rial injury. Consistent with this hypothesis, Hatton et al.
(38) demonstrated uptake of radiolabeled HCII into the
vessel wall and formation of high-Mr complexes (pre-
sumably thrombin-HCII) following damage to the rabbit
aortic endothelium with a balloon catheter. Future exper-
iments in which HCII-deficient mice are reconstituted
with native recombinant HCII along with variants defec-
tive in binding to dermatan sulfate or heparin (39, 40)
may provide direct evidence for activation of HCII by gly-
cosaminoglycans in the carotid thrombosis model.
The identification of an abnormal phenotype in the
HCII knockout mouse does not eliminate the impor-
tance of searching for additional abnormalities. Thus,
it will be important to determine if HCII-deficient mice
are more susceptible to venous thrombosis after
endothelial injury or develop thrombi spontaneously
within normal blood vessels when another throm-
bophilic mutation (e.g., homozygosity for factor VLeiden)
is also present. Since HCII inhibits arterial thrombosis
after endothelial injury, it might affect other arterial
processes such as atherosclerosis, in which abnormali-
ties in HCII-activating glycosaminoglycans have been
demonstrated (13). The HCII-deficient mouse provides
a valuable tool with which to explore the regulation of
physiologic processes involving thrombin.
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